Radiological imaging and non-surgical local treatments for cholangiocarcinoma

Abstract

Cholangiocarcinoma (CC) is a malignancy with a very heterogeneous spectrum of morphopathological and prognostic characteristics. Diagnostic imaging is fundamental for early detection, preoperative staging, and resectability assessment, as well as early recognition of prognostic factors. Radical surgical treatment is limited by disease stage and technical feasibility. Interventional radiology has acquired a critical function in addressing disease control and survival improvement through loco-regional therapies, specifically in the setting of intrahepatic CC. In this review, we will describe the current state of art of diagnostic imaging, focusing on intrahepatic CC and proximal extrahepatic CC, and delineate the available loco-regional therapies strategies for unresectable intrahepatic CC.

Keywords

Cholangiocarcinoma / diagnostic imaging / loco-regional therapies / ablation / embolization

References

[1] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88 PMCID:PMC7447603

[2] Banales JM,Carpino G.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016;13:261-80

[3] Bertuccio P,Carioli G.Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.J Hepatol2019;71:104-14

[4] Khan SA,Brandi G.Cholangiocarcinoma: epidemiology and risk factors.Liver Int2019;39 Suppl 1:19-31

[5] Jang MH,Kim H.Intrahepatic cholangiocarcinoma arising in Caroli’s disease.Clin Mol Hepatol2014;20:402-5 PMCID:PMC4278073

[6] Petrick JL,Altekruse SF.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: as population-based study in SEER-Medicare.PLoS One2017;12:e0186643 PMCID:PMC5648218

[7] Fernández-Ruiz M,Colina-Ruizdelgado F.Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma.World J Gastroenterol2009;15:5279-86 PMCID:PMC2776854

[8] Joo I,Lee SM,Park JY.Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.J Magn Reson Imaging2016;44:1330-8

[9] Joo I.Imaging bile duct tumors: pathologic concepts, classification, and early tumor detection.Abdom Imaging2013;38:1334-50

[10] Seo N,Lee SS.Sclerosing cholangitis: clinicopathologic features, imaging spectrum, and systemic approach to differential diagnosis.Korean J Radiol2016;17:25-38 PMCID:PMC4720808

[11] Kim JY,Lee TY.Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging.Am J Gastroenterol2008;103:1145-51

[12] Moon CM,Chung JB.Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.J Gastroenterol Hepatol2008;23:759-65

[13] Waisberg DR,Nacif LS.Resection for intrahepatic cholangiocellular cancer: new advances.Transl Gastroenterol Hepatol2018;3:60 PMCID:PMC6182028

[14] Tamandl D,Gruenberger B,Klinger M.Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma.Ann Surg Oncol2008;15:2787-94

[15] Park JJ,Kwon JE.Clinical outcomes and factors related to resectability and curability of EMR for early colorectal cancer.Gastrointest Endosc2011;74:1337-46

[16] Kolarich AR,George TJ Jr.Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004-2015: an NCDB analysis.J Gastrointest Oncol2018;9:536-45 PMCID:PMC6006029

[17] Boehm LM,Miura JT.Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma.J Surg Oncol2015;111:213-20

[18] Kuriyama N,Gyoten K.Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.BMC Cancer2020;20:405 PMCID:PMC7216500

[19] Anderson B.Surgical considerations of hilar cholangiocarcinoma.Surg Oncol Clin N Am2019;28:601-17

[20] Ayuso JR,Darnell A.Imaging bile duct tumors: staging.Abdom Imaging2013;38:1071-81

[21] Hennedige TP,Venkatesh SK.Imaging of malignancies of the biliary tract- an update.Cancer Imaging2014;14:14 PMCID:PMC4331820

[22] Razumilava N.Classification, diagnosis, and management of cholangiocarcinoma.Clin Gastroenterol Hepatol2013;11:13-21.e1; quiz e3 PMCID:PMC3596004

[23] Ruys AT,Engelbrecht MR,Stoker J.Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis.Br J Radiol2012;85:1255-62 PMCID:PMC3487057

[24] Clements O,Kim JU,Khan SA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.J Hepatol2020;72:95-103

[25] Uchida M,Tomita N,Hayabuchi N.Hilar and suprapancreatic cholangiocarcinoma: value of 3D angiography and multiphase fusion images using MDCT.AJR Am J Roentgenol2005;184:1572-7

[26] Matos C,Bali MA.Magnetic resonance imaging of biliary tumors.Magn Reson Imaging Clin N Am2010;18:477-96, x

[27] Kim HJ,Byun JH.Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques.Radiology2015;274:712-22

[28] Lee KH,Park JH.MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.Korean J Radiol2013;14:894-904 PMCID:PMC3835636

[29] Shimada K,Hirokawa Y,Shibata T.Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases.Eur Radiol2010;20:2690-8

[30] Olthof SC,Clasen S,Nikolaou K.Imaging of cholangiocarcinoma.Visc Med2016;32:402-10 PMCID:PMC5290452

[31] Edge S. American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York: Springer; 2010.

[32] Park HS,Choi JY.Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography.AJR Am J Roentgenol2008;190:396-405

[33] Jhaveri KS.MRI of cholangiocarcinoma.J Magn Reson Imaging2015;42:1165-79

[34] Cui XY.Role of diffusion-weighted magnetic resonance imaging in the diagnosis of extrahepatic cholangiocarcinoma.World J Gastroenterol2010;16:3196-201 PMCID:PMC2896758

[35] Razumilava N,Lindor KD.Cancer surveillance in patients with primary sclerosing cholangitis.Hepatology2011;54:1842-52 PMCID:PMC3205332

[36] Aljiffry M,Walsh M,Alwayn I.Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.J Am Coll Surg2009;208:134-47

[37] Joo I,Yoon JH.Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges.Radiology2018;288:7-13

[38] Choi KS,Joo I,Choi BI.Evaluation of perihilar biliary strictures: does DWI provide additional value to conventional MRI?.AJR Am J Roentgenol2015;205:789-96

[39] Choi EK,Kim SH.The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease.Clin Nucl Med2013;38:e106-11

[40] Wang S,Wang Q.18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice.Hepatobiliary Pancreat Dis Int2015;14:516-22

[41] Furukawa H,Asakura-Yokoe K.Preoperative staging of biliary carcinoma using 18F-fluorodeoxyglucose PET: prospective comparison with PET+CT, MDCT and histopathology.Eur Radiol2008;18:2841-7

[42] Anderson CD,Pinson CW,Chari RS.Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma.J Gastrointest Surg2004;8:90-7

[43] Chong YS,Lee MW.Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.Clin Radiol2012;67:766-73

[44] Inchingolo R,Gatti M.Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma.World J Gastroenterol2020;26:4261-71 PMCID:PMC7422539

[45] Oliveira IS,Everett JM,Harisinghani MG.Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management.Abdom Radiol (NY)2017;42:1637-49

[46] Türkoğlu MA,Sugiura T.The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: a clinicopathologic and immunohistochemical study.Surgery2016;160:683-90

[47] Ariizumi S,Takahashi Y.Mass-forming intrahepatic cholangiocarcinoma with marked enhancement on arterial-phase computed tomography reflects favorable surgical outcomes.J Surg Oncol2011;104:130-9

[48] Lee J,Kang TW,Choi D.Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker.Radiology2016;281:119-28

[49] Koh J,Nahm JH.Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.Eur Radiol2016;26:407-16

[50] Asayama Y,Irie H.Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma.Radiology2006;238:150-5

[51] Kajiyama K,Takenaka K,Tsuneyoshi M.The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of ‘scirrhous-type’ and ‘nonscirrhous-type’ growth.Am J Surg Pathol1999;23:892-902

[52] Pandey A,Ghasabeh MA.Baseline volumetric multiparametric MRI: can it be used to predict survival in patients with unresectable intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization?.Radiology2018;289:843-53

[53] Yoo J,Bae JS.Prediction of prognosis and resectability using MR imaging, clinical, and histopathological findings in patients with perihilar cholangiocarcinoma.Abdom Radiol (NY)2021;46:4159-69

[54] Slakey DP.Radiofrequency ablation of recurrent cholangiocarcinoma.Am Surg2002;68:395-7

[55] Bridgewater J,Khan SA.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J Hepatol2014;60:1268-89

[56] Xu C,Xu W.Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results.Int J Hyperthermia2019;36:351-8

[57] Carrafiello G,Cotta E.Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience.Cardiovasc Intervent Radiol2010;33:835-9

[58] Andreano A.A comparison of direct heating during radiofrequency and microwave ablation in ex vivo liver.Cardiovasc Intervent Radiol2013;36:505-11 PMCID:PMC3437379

[59] Yousaf A,Eliahoo J,Khan SA.Ablative therapy for unresectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.J Clin Exp Hepatol2019;9:740-8 PMCID:PMC6926226

[60] Sweeney J,El-Haddad G.Ablation of intrahepatic cholangiocarcinoma.Semin Intervent Radiol2019;36:298-302 PMCID:PMC6823041

[61] Yu MA,Yu XL.Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma.Eur J Radiol2011;80:548-52

[62] Ni JY,Zhang TQ,Jiang XY.Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma.Int J Hyperthermia2019;36:328-36

[63] Yu MA,Yu XL.Liver abscess as a complication of microwave ablation for liver metastatic cholangiocarcinoma after bilioenteric anastomosis.Int J Hyperthermia2011;27:503-9

[64] Lucatelli P,Guiu B,van Delden O.CIRSE standards of practice on hepatic transarterial chemoembolisation.Cardiovasc Intervent Radiol2021;44:1851-67

[65] Kiefer MV,McNally M.Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study.Cancer2011;117:1498-505

[66] Shen WF,Liu Q,Huang YQ.Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.World J Surg2011;35:2083-91

[67] Odisio BC,Aloia TA.Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation.J Gastrointest Surg2016;20:1428-34 PMCID:PMC4938743

[68] Ierardi AM,Patella F.The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma.Med Oncol2017;34:11

[69] Cohen MJ,Barak O.Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma.World J Gastroenterol2013;19:2521-8 PMCID:PMC3646143

[70] Aliberti C,Tilli M.Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results.Cardiovasc Intervent Radiol2008;31:883-8

[71] Venturini M,Agostini G.Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.Br J Radiol2016;89:20160247 PMCID:PMC5124834

[72] Kennedy A,Sangro B,Salem R.Radioembolization for the treatment of liver tumors general principles.Am J Clin Oncol2012;35:91-9

[73] Kennedy A,Salem R.Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.Int J Radiat Oncol Biol Phys2007;68:13-23

[74] Buettner S,Margonis GA.Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis.J Vasc Interv Radiol2020;31:1035-43.e2

[75] Al-Adra DP,Axford SJ,Kneteman N.Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.Eur J Surg Oncol2015;41:120-7 PMCID:PMC4316196

[76] Ibrahim SM,Lewandowski RJ.Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study.Cancer2008;113:2119-28

[77] Hoffmann RT,Schön A.Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.Cardiovasc Intervent Radiol2012;35:105-16

[78] Saxena A,Chua TC,Morris DL.Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.Ann Surg Oncol2010;17:484-91

[79] Cucchetti A,Mosconi C.Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: a meta-regression study.Liver Int2017;37:1056-64

[80] Gangi A,Hatfield N.Intrahepatic cholangiocarcinoma treated with transarterial Yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study.J Vasc Interv Radiol2018;29:1101-8 PMCID:PMC7771272

[81] Helmberger T,Pech M.On behalf of the CIRT Steering CommitteeOn behalf of the CIRT Principal InvestigatorsClinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT).Cardiovasc Intervent Radiol2021;44:21-35 PMCID:PMC7728645

[82] Riaz A,Kulik LM.Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.J Vasc Interv Radiol2009;20:1121-30; quiz 1131

[83] Riby D,Bergeat D.Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma.Ann Surg Oncol2020;27:3729-37

[84] Brown DB,Sacks D.Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.J Vasc Interv Radiol2006;17:225-32

[85] Kasai K,Suzuki Y.Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.Ann Surg Oncol2014;21:3638-45

[86] Cantore M,Fiorentini G.Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.Cancer2005;103:1402-7

[87] Cai Z,Zhao C.Survival comparisons of hepatic arterial infusion chemotherapy with mFOLFOX and transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma.Front Oncol2021;11:611118 PMCID:PMC8047640

[88] Hughes MS,Faries M.Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases.Ann Surg Oncol2016;23:1309-19 PMCID:PMC8185532

[89] Marquardt S,Brüning R.Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.Eur Radiol2019;29:1882-92

[90] Koch C,Bechstein WO.Poor prognosis of advanced cholangiocarcinoma: real-world data from a tertiary referral center.Digestion2020;101:458-65

[91] Mosconi C,Ascanio S.Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study.Br J Cancer2016;115:297-302 PMCID:PMC4973156

[92] Edeline J,Guiu B.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial.JAMA Oncol2020;6:51-9 PMCID:PMC6824230

[93] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[94] Lamarca A,Wasan HS.Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials.J Natl Cancer Inst2020;112:200-10

[95] Cercek A,Tan BR.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial.JAMA Oncol2020;6:60-7 PMCID:PMC6824231